Pulmotect, Inc. is a clinical stage biotechnology company developing products that boost the body's innate immune system to protect against a wide range of lung infections. With a global licence from Texas A&M and University of Texas MD Cancer Center. the firm is organized around emerging science of innate immunity in the lungs, Pulmotect's technologies stimulate the bodys natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). Pulmotects lead product, PUL-042, is an inhaled therapeutic that stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days to include bacteria, fungi, and viral pathogens. Pulmotects initial market focus is on the reduction of chronic obstructive pulmonary disease (COPD) exacerbations, which are characterized by an acute worsening of symptoms mostly precipitated by a bacterial or viral infec
